Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Nuvation Bio (NUVB) EBIT (2023 - 2025)

Historic EBIT for Nuvation Bio (NUVB) over the last 3 years, with Q3 2025 value amounting to -$56.4 million.

  • Nuvation Bio's EBIT fell 1732.4% to -$56.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$233.0 million, marking a year-over-year increase of 5836.24%. This contributed to the annual value of -$592.6 million for FY2024, which is 49368.38% down from last year.
  • Nuvation Bio's EBIT amounted to -$56.4 million in Q3 2025, which was down 1732.4% from -$63.6 million recorded in Q2 2025.
  • In the past 5 years, Nuvation Bio's EBIT ranged from a high of -$20.2 million in Q1 2024 and a low of -$470.4 million during Q2 2024
  • Moreover, its 3-year median value for EBIT was -$48.1 million (2024), whereas its average is -$79.2 million.
  • In the last 5 years, Nuvation Bio's EBIT plummeted by 170010.33% in 2024 and then soared by 8648.15% in 2025.
  • Nuvation Bio's EBIT (Quarter) stood at -$20.8 million in 2023, then tumbled by 158.95% to -$53.9 million in 2024, then fell by 4.62% to -$56.4 million in 2025.
  • Its last three reported values are -$56.4 million in Q3 2025, -$63.6 million for Q2 2025, and -$59.0 million during Q1 2025.